A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Alzheimer´s Disease

In brief

The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).

Key facts

Study ID
NCT00818662
Run by
Baxalta now part of Shire
People needed
390
Starts
2008-12-19
Expected to finish
2012-12-10
Last updated by the study team
2021-05-19

Who can join

Age: 50 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.